JC2-11
JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1[1].
Product Specifications
CAS Number
937820-89-8
UNSPSC
12352005
Target
AIM2; NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jc2-11.html
Purity
98.03
Solubility
DMSO : ≥ 100 mg/mL
Smiles
COC1=CC(/C=C/C(C2=CC(F)=C(C=C2)OC)=O)=CC=C1O
Molecular Formula
C17H15FO4
Molecular Weight
302.30
References & Citations
[1]Lee G, et al, JC2-11, a benzylideneacetophenone derivative, attenuates inflammasome activation. Sci Rep. 2022 Dec 28;12 (1) :22484.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NLRP3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
